A May 2026 international consensus adopted the name polyendocrine metabolic ovarian syndrome (PMOS). Many of the studies discussed here use the previous name, polycystic ovary syndrome (PCOS) [1]. Our review of GLP-1 prescribing records includes prescriptions after a PCOS diagnosis. Prescription records and randomized trials answer different questions.
What randomized studies found
A systematic review of 11 randomized trials found BMI was 1.38 kg/m² lower (95% CI: 0.38 to 2.39 kg/m² lower) with GLP-1 receptor agonists as an add-on treatment, compared with control groups. The authors rated the evidence as low certainty and found too little evidence to draw conclusions about glucose, insulin, excessive hair growth or menstrual regularity [2].
The comparison with metformin describes the outcomes measured in studies of the two treatments. Check which outcome a study measured before using it to compare treatment options.
In a small open-label randomized trial (n = 64) of women with PCOS-related infertility and overweight or obesity, adding semaglutide to metformin improved menstrual regularity during short follow-up compared with metformin alone [3]. That finding cannot establish a benefit for pregnancy or live birth. The international guideline supports considering anti-obesity medication for higher weight according to general-population guidance and recommends using it for reproductive outcomes only in research settings [4].
What the tirzepatide cohort can tell us
Researchers studying tirzepatide in a UK online weight-management program reported similar weight-loss trajectories in women with and without self-reported PCOS. Everyone in the comparison received tirzepatide. PCOS status and weight were self-reported, and the study did not measure whether menstrual cycles, androgen symptoms or fertility improved [5].
What prescribing records and program fees tell you
In one Polish private health network, the proportion starting an incretin-based medicine within a year of PCOS diagnosis rose from 0.14% in 2018 to 5.97% in 2024. Among incretin users, 11.5% had a coded type 2 diabetes diagnosis. That code alone does not establish the reason for a prescription [6].
If you are comparing PCOS Sisters’ GLP-1 management program with another form of care, its advertised starting price is $150 per month and membership is required. Ask which membership and pharmacy charges apply to your prescription [7]. If using insurance, the GLP-1 insurance coverage guide explains how a plan can set different rules by product and indication.